Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 2/20 | 0.55 |
| ▸ | MAG | P20916 | 5/20 | 0.55 |
| ▸ | NANP | Q8TBE9 | 1/20 | 0.53 |
| ▸ | SELL | P14151 | 1/20 | 0.52 |
| ▸ | SELP | P16109 | 1/20 | 0.52 |
| ▸ | CD22 | P20273 | 12/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29732933 | 1.00 | SIGLEC7 (0.55) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL29410578 | 1.00 | SIGLEC7 (0.55) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL15177450 | 1.00 | SIGLEC7 (0.55) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL16298815 | 1.00 | SIGLEC7 (0.55) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL31309218 | 0.94 | SIGLEC7 (0.57) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL29437857 | 0.94 | SIGLEC7 (0.57) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL29437858 | 0.94 | SIGLEC7 (0.57) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL29397098 | 0.94 | SIGLEC7 (0.57) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL29883057 | 0.94 | SIGLEC7 (0.57) | SIGLEC7MAGNANPSELLSELP | |
| SCHEMBL14628033 | 0.93 | SELL (0.54) | SIGLEC7MAGNANPSELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941480-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | Score Pharma Inc. (US) | 2022-01-26 | — | — | EP | claimed |
| US-20250326838-A1 | ANTI-SIGLEC15 ANTIBODY AND USE THEREOF | CSPC Megalith Biopharmaceutical Co., Ltd. (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4496808-A1 | ANTIBODIES WITH ENGINEERED O-GLYCOSYLATION SEQUONS FOR SITE-SPECIFIC CONJUGATION | National Research Council of Canada (CA) | 2025-01-29 | — | — | EP | disclosed |
| EP-4448559-A1 | CD44 GLYCOEPITOPES AND CHIMERIC VACCINE GLYCOCONJUGATES FOR CANCER THERAPY AND SYNTHESIS METHODS THEREOF | I3S - Instituto de Investigação e Inovação em Saúde, Associação (PT) | 2024-10-23 | — | — | EP | disclosed |
| EP-2099480-B2 | MICROORGANISMS OF FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES | TE BIOS CO LTD (KR) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023178421-A1 | ANTIBODIES WITH ENGINEERED O-GLYCOSYLATION SEQUONS FOR SITE-SPECIFIC CONJUGATION | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-09-28 | — | — | WO | disclosed |
| US-11739136-B2 | Inducible dominant negative PD-1 and uses in adoptive cell therapy | INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS, LTD. (KY) | 2023-08-29 | — | — | US | disclosed |
| CN-116375873-A | Anti-human Siglec-9 monoclonal antibody and application thereof | 珠海市丽珠单抗生物技术有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023033664-A1 | CD44 GLYCOEPITOPES AND CHIMERIC VACCINE GLYCOCONJUGATES FOR CANCER THERAPY AND SYNTHESIS METHODS THEREOF | I3S - INSTITUTO DE INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE, ASSOCIAÇÃO (PT) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022224241-A1 | CHIMERIC ANTIGEN RECEPTORS TO SIALYL-TN GLYCAN ANTIGEN | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022179483-A1 | PREPARATION OF SIGLEC-15 BINDING PROTEIN AND USE THEREOF | 上海济煜医药科技有限公司 | 2022-09-01 | — | — | WO | disclosed |
| US-20220168419-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES AND CANCERS | YALE UNIVERSITY (US) | 2022-06-02 | — | — | US | disclosed |
| EP-3941480-A1 | COMPOUNDS FOR INHIBITING FUCOSYLATION AND METHODS FOR USING THE SAME | Score Pharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |